thymalfasin and Neoplasms

thymalfasin has been researched along with Neoplasms* in 26 studies

Reviews

14 review(s) available for thymalfasin and Neoplasms

ArticleYear
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients.
    Future oncology (London, England), 2021, Volume: 17, Issue:9

    We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase (Eudract no. 2020-006020-13). We aim to offer new hope for this incurable disease, especially to frail patient population, such as patients with cancer. The hypothesis of an effective prophylactic approach to COVID-19 would have immediate clinical relevance, especially given the lack of curative approaches. Moreover, in the 'COVID-19 vaccine race era' both clinical and biological results coming from the PROTHYMOS trials could even support the rationale for future combinatorial approaches, trying to rise vaccine efficacy in frail individuals.

    Topics: Adjuvants, Immunologic; Clinical Trials, Phase II as Topic; COVID-19; COVID-19 Drug Treatment; Humans; Neoplasms; Randomized Controlled Trials as Topic; Research Design; SARS-CoV-2; Thymalfasin

2021
Serum thymosin alpha 1 levels in normal and pathological conditions.
    Expert opinion on biological therapy, 2018, Volume: 18, Issue:sup1

    Thymosin alpha 1 (Ta1) is a natural occurring peptide hormone that is crucial for the maintenance of the organism homeostasis. It has been chemically synthesized and used in diseases where the immune system is hindered or malfunctioning.. Many clinical trials investigate the Ta1 effects in patients with cancer, infectious diseases and as a vaccine enhancer. The number of diseases that could benefit from Ta1 treatment is increasing. To date, questions remain about the physiological basal levels of Ta1 and the most effective dose and schedule of treatment. Evidence is growing that diseases characterized by deregulation of immune and/or inflammatory responses are associated with serum levels of Ta1 significantly lower than those of healthy individuals: to date, B hepatitis, psoriatic arthritis, multiple sclerosis and sepsis. The sputum of cystic fibrosis patients contains lower levels of Ta1 than healthy controls. These data are consistent with the role of Ta1 as a regulator of immunity, tolerance and inflammation.. Low serum Ta1 levels are predictive and/or associated with different pathological conditions. In case of Ta1 treatment, it is crucial to know the patient's baseline serum Ta1 level to establish effective treatment protocols and monitor their effectiveness over time.

    Topics: Adjuvants, Immunologic; Communicable Diseases; Disease; Hepatitis B; Homeostasis; Humans; Neoplasms; Sepsis; Thymalfasin; Vaccines

2018
Immune Modulation with Thymosin Alpha 1 Treatment.
    Vitamins and hormones, 2016, Volume: 102

    Thymosin alpha 1 (Ta1) is a peptide originally isolated from thymic tissue as the compound responsible for restoring immune function to thymectomized mice. Ta1 has a pleiotropic mechanism of action, affecting multiple immune cell subsets that are involved in immune suppression. Ta1 acts through Toll-like receptors in both myeloid and plasmacytoid dendritic cells, leading to activation and stimulation of signaling pathways and initiation of production of immune-related cytokines. Due to the immune stimulating effects of Ta1, the compound would be expected to show utility for treatment of immune suppression, whether related to aging or to diseases such as infection or cancer. Extensive studies in both the preclinical and clinical setting will be summarized in the subsequent sections. These studies have demonstrated improvements in immune system cell subsets and the potential of Ta1 for the treatment of a range of diseases.

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Disease Models, Animal; Humans; Immunity; Immunologic Deficiency Syndromes; Immunosuppression Therapy; Infections; Mice; Neoplasms; Thymalfasin; Thymosin; Vaccines

2016
Thymosin α1 and cancer: action on immune effector and tumor target cells.
    Annals of the New York Academy of Sciences, 2012, Volume: 1269

    Since it was first identified, thymosin alpha 1 (Tα1) has been characterized to have pleiotropic effects on several pathological conditions, in particular as a modulator of immune response and inflammation. Several properties exerted by Tα1 may be attributable to a direct action on lymphoid cells. Tα1 has been shown to exert an immune modulatory activity on both T cell and natural killer cell maturation and to have an effect on functions of mature lymphocytes, including stimulating cytokine production and cytotoxic T lymphocyte-mediated cytotoxic responses. In previous studies we have shown that Tα1 increases the expression of major histocompatibility complex class I surface molecules in murine and human tumor cell lines and in primary cultures of human macrophages. In the present paper, we describe preliminary data indicating that Tα1 is also capable of increasing the expression of tumor antigens in both experimental and human tumor cell lines. This effect, which is exerted at the level of the target tumor cells, represents an additional factor increasing the antitumor activity of Tα1.

    Topics: Antigens, Neoplasm; Cell Line, Tumor; Humans; Immunologic Factors; Killer Cells, Natural; Neoplasms; T-Lymphocytes; Thymalfasin; Thymosin

2012
Thymic peptides for treatment of cancer patients.
    The Cochrane database of systematic reviews, 2011, Feb-16, Issue:2

    Purified thymus extracts (pTE) and synthetic thymic peptides (sTP) are thought to enhance the immune system of cancer patients in order to fight the growth of tumour cells and to resist infections due to immunosuppression induced by the disease and antineoplastic therapy.. To evaluate the effectiveness of pTE and sTP for the management of cancer.. We searched CENTRAL (The Cochrane Library 2010, Issue 3), MEDLINE, EMBASE, AMED, BIOETHICSLINE, BIOSIS, CATLINE, CISCOM, HEALTHSTAR, HTA, SOMED and LILACS (to February 2010).. Randomised trials of pTE or sTP in addition to chemotherapy or radiotherapy, or both, compared to the same regimen with placebo or no additional treatment in adult cancer patients.. Two authors independently extracted data from published trials. We derived odds ratios (OR) from overall survival (OS) and disease-free survival (DFS) rates, tumour response (TR) rates, and rates of adverse effects (AE) related to antineoplastic treatments. We used a random-effects model for meta-analysis.. We identified 26 trials (2736 patients). Twenty trials investigated pTE (thymostimulin or thymosin fraction 5) and six trials investigated sTP (thymopentin or thymosin α(1)). Twenty-one trials reported results for OS, six for DFS, 14 for TR, nine for AE and 10  for safety of pTE and sTP. Addition of pTE conferred no benefit on OS (RR 1.00, 95% CI 0.79 to 1.25); DFS (RR 0.97, 95% CI 0.82 to 1.16); or TR (RR 1.07, 95% CI 0.92 to 1.25). Heterogeneity was moderate to high for all these outcomes. For thymosin α(1) the pooled RR for OS was 1.21 (95% CI 0.94 to 1.56, P = 0.14), with low heterogeneity; and 3.37 (95% CI 0.66 to 17.30, P = 0.15) for DFS, with moderate heterogeneity. The pTE reduced the risk of severe infectious complications (RR 0.54, 95% CI 0.38 to 0.78, P = 0.0008; I² = 0%). The RR for severe neutropenia in patients treated with thymostimulin was 0.55 (95% CI 0.25 to 1.23,  P = 0.15). Tolerability of pTE and sTP was good. Most of the trials had at least a moderate risk of bias.. Overall, we found neither evidence that the addition of pTE to antineoplastic treatment reduced the risk of death or disease progression nor that it improved the rate of tumour responses to antineoplastic treatment. For thymosin α(1), there was a trend for a reduced risk of dying and of improved DFS. There was preliminary evidence that pTE lowered the risk of severe infectious complications in patients undergoing chemotherapy or radiotherapy.

    Topics: Adjuvants, Immunologic; Adult; Disease-Free Survival; Female; Humans; Immune System; Immunocompromised Host; Male; Neoplasms; Peptides; Thymalfasin; Thymopentin; Thymosin; Thymus Extracts; Thymus Gland

2011
Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof.
    Annals of the New York Academy of Sciences, 2010, Volume: 1194

    The hepatitis C virus (HCV) is a global public health problem, with chronic infection leading to development of cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC). Treatment of HCV is suboptimal with overall response rates of slightly greater than 50% when patients are treated with pegylated interferon alfa and ribavirin. Thymosin alpha 1 (Talpha1; TA-1) is an immunomodulatory peptide with intrinsic activities that might improve treatment outcomes for HCV by incorporation of this agent in current treatment paradigms. An extensive body of literature supports a possible role for this agent in difficult to treat populations. However, clinical trials to date have failed to conclusively support the role of TA-1 in combination interferon-based therapies. Therefore, the promise of TA-1 adjunctive therapy for HCV remains, but the proof will require investment in large randomized clinical trials of appropriate patient populations.

    Topics: Carcinoma, Hepatocellular; Chronic Disease; Clinical Trials as Topic; Hepacivirus; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Neoplasms; Randomized Controlled Trials as Topic; Ribavirin; Thymalfasin; Thymosin; Treatment Outcome

2010
Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy.
    Annals of the New York Academy of Sciences, 2010, Volume: 1194

    Thymosin alpha1 (Talpha1) is a 28 amino acid biologically active protein with pleiotropic immune enhancing activity. IRX-2 is a primary cell-derived biologic containing multiple cytokines that enhance dendritic cell maturation, promote T-cell growth and differentiation, and inhibit tumor-mediated apoptosis of T cells. IRX-2 is being developed as an immunotherapeutic agent as a novel T-cell adjuvant platform for vaccines as well. Based on their biological activities, thymosin alpha1 and IRX-2 were predicted to exhibit synergistic effects when evaluated in animal and human studies. In animal studies, the combination of IRX-2 and Talpha1 (IRX-3) increased T-cell numbers compared to either alone during recovery from hydrocortisone mediated reduction. IRX-3 further enhanced reduction in tumor burden following chemotherapy compared to IRX-2. Based on these studies, IRX-3 is predicted to be especially important in a setting where reversal of immune suppression due to the presence of tumor, irradiation, and/or chemotherapy is likely to be an important factor in cytokine activity.

    Topics: Adjuvants, Immunologic; Animals; Apoptosis; Cell Differentiation; Cytokines; Dendritic Cells; Humans; Mice; Neoplasms; T-Lymphocytes; Thymalfasin; Thymosin

2010
Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance.
    Annals of the New York Academy of Sciences, 2007, Volume: 1112

    Thymosin alpha1 (Talpha1), first described and characterized by Allan Goldstein in 1972, is used worldwide for the treatment of some immunodeficiencies, malignancies, and infections. Although Talpha1 has shown a variety of effects on cells and pathways of the immune system, its central role in modulating dendritic cell (DC) function has only recently been appreciated. As DCs have the ability to sense infection and tissue stress and to translate collectively this information into an appropriate immune response, an action on DCs would predict a central role for Talpha1 in inducing different forms of immunity and tolerance. Recent results have shown that Talpha1: (a) primed DCs for antifungal Th1 resistance through Toll-like receptor (TLR)/MyD88-dependent signaling and this translated in vivo in protection against aspergillosis; (b) activated plasmacytoid DCs (pDC) via the TLR9/MyD88-dependent viral recognition, thus leading to the activation of interferon regulatory factor 7 and the promotion of the IFN-alpha/IFN-gamma-dependent effector pathway, which resulted in vivo in protection against primary murine cytomegalovirus infection; (c) induced indoleamine 2,3-dioxygenase activity in DCs, thus affecting tolerization toward self as well as microbial non-self-antigens, and this resulted in vivo in transplantation tolerance and protection from inflammatory allergy. Talpha1 is produced in vivo by cleavage of prothymosin alpha in diverse mammalian tissues. Our data qualify Talpha1 as an endogenous regulator of immune homeostasis and suggest that instructive immunotherapy with Talpha1, via DCs and tryptophan catabolism, could be at work to control inflammation, immunity, and tolerance in a variety of clinical settings.

    Topics: Acquired Immunodeficiency Syndrome; Animals; Aspergillosis; Dendritic Cells; HIV Infections; Homeostasis; Humans; Hypersensitivity; Immunity, Innate; Inflammation; Mycoses; Neoplasms; Signal Transduction; Th1 Cells; Thymalfasin; Thymosin; Thymus Gland

2007
Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer.
    International immunopharmacology, 2003, Volume: 3, Issue:8

    Multiple therapeutic approaches have been tested in different experimental tumour models and in human cancers. Most part of them are based on the hypothesis that the inhibition of tumour growth requires a strong immune response in which a main role is played by CTLs. It is known, however, that an efficient CTL response requires expression of tumour antigens, MHC class I surface molecules presentation, expression of different co-stimulatory molecules and a sustained generation and proliferation of specific cytotoxic CD8+ cells with an efficient CD4+ cooperation. In this context, our group has extensively explored a protocol of combined therapy consisting of the use of chemotherapeutic agents associated with thymosin alpha 1 (Talpha 1) and different cytokines, whose efficacy has been demonstrated in experimental models as well as in human cancers. In this manuscript, the main data supporting a pivotal role of Talpha 1 in such combination protocols are reviewed. In particular, a special mention of the molecular mechanisms underlying the effects of Talpha 1 on immune effector cells as well as on target tumour cells is provided. These data contribute to explain the mechanism of action of Talpha 1, when used in combination therapy, for the treatment of cancer and provide new insights in predicting further possible applications of this peptide in other pathological conditions.

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Disease-Free Survival; Humans; Neoplasms; Thymalfasin; Thymosin

2003
Thymosin alpha1. SciClone Pharmaceuticals.
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:5

    Thymosin alpha1 (Talpha1), a synthetic 28-amino acid peptide with multiple biological activities primarily directed towards immune response enhancement, was originally developed by Alpha 1 Biomedicals for the treatment of hepatitis B virus (HBV) infection. SciClone developed and launched Talpha1, under the trade name Zadaxin, for the treatment of HBV and hepatitis C virus (HCV) infections. The drug is also being developed for the treatment of non-small cell lung cancer (NSCLC), hepatocellular carcinoma, AIDS and malignant melanoma. Talpha1 is able to potentiate the action of cytokines and also reduce the hematological toxicity of cytotoxic drug therapy (cyclophosphamide-, 5-fluorouracil-, dacarbazine- or ifosfamide-based regimens). These studies also demonstrated the mechanism of action of Talpha1 and its role as an immune system enhancer. By July 2001, it was in phase III trials in the US in combination with PEGylated interferon-alpha, and later the same month it was approved in the Philippines. SciClone received expanded approval for HBV and HCV infection in Mexico in July 2001. Talpha1 has been launched in Argentina, China, Peru, the Philippines and Singapore for the treatment of chronic HBV infection. The product subsequently received expanded approval for the treatment of both HBV and HCV infection in Argentina. Marketing approval was granted in India for HBV infection in February 2001. The company was working to expand this approval to include HCV infection. In March 2000, approval for treatment of HBV infection was granted in Thailand, Laos and Malta. Approval was also granted in Sri Lanka and Brunei in August 1999. In September 2000, SciClone announced that approval had been expanded to include the treatment of HCV infection as well as the previously approved HBV indication in both Peru and Sri Lanka. In January 1999, SciClone received approval for Talpha1 in Venezuela for the treatment of HBV and HCV infection. The company also filed a marketing application in New Zealand for Talpha1 to treat HBV infection. The drug was approved in South Korea in April 2000, as an influenza vaccine adjuvant and this was expected to be expanded to indude use for treatment of both HBV and HCV infections. In July 2001, it was approved in In September and October 2000, SciClone was granted patents in Mexico and Canada, respectively, for the use of Talpha1 for the treatment of HCV infection. In June 2000, SciClone was issued a Notice of Allowance by the US Patent and

    Topics: Adjuvants, Immunologic; Animals; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Injections, Subcutaneous; Neoplasms; Structure-Activity Relationship; Thymalfasin; Thymosin; Virus Diseases

2002
Review of thymic hormones in cancer diagnosis and treatment.
    International journal of immunopharmacology, 2000, Volume: 22, Issue:4

    The thymus is an endocrine organ. A unified, physiological concept of humoral regulations of the immune response has emerged in the last three decades. The thymus is the major site of production of immunocompetent T lymphocytes from their hematopoietic stem cells. This complex process required direct cell to cell, receptor based interactions, as well as in situ paracrine information via the numerous cytokines and thymic hormones produced by the cells of thymic microenvironment. Thymic hormones induce in situ T-cell marker differentiation, expression and functions. These polypeptide hormones have also been shown by means of immunocytochemistry to localize in the reticulo-epithelial (RE) cells of the thymic cellular microenvironment. Due to the great complexity of the intrathymic maturation sequence of T lymphocytes and the diverse immunophenotypically unique subpopulations of T lymphocytes, it is quite unlikely that a single thymic humoral factor could control all of the molecular steps and cell populations involved. It is much more likely that an extremely rich and diverse, but genetically determined, milieu is present within the thymus, and that thus the control of intrathymic T lymphocyte maturation and the functional maturation of T cells involves the orchestral interaction of various thymic-specific factors and other molecules during the differentiation process. Thymosin fraction 5 and its constituent peptides influence several properties of lymphocytes including cyclic nucleotide levels, migration inhibitory factor production, T-dependent antibody production, as well as the expression of various cell surface maturation/differentiation markers. Recently, derivatives of thymic hormones, mostly of thymosins, have been detected as products of neoplastically transformed cells and employed in the early diagnosis of neoplasms. In clinical trials, thymic hormones strengthen the effects of immunomodulators in immunodeficiencies, autoimmune diseases, and neoplastic malignancies. Combined chemo-immunotherapeutical anti-cancer treatment seems to be more efficacious than chemotherapy alone, and the significant hematopoietic toxicity associated with most chemotherapeutical clinical trials can be reduced significantly by the addition of immunotherapy.

    Topics: Biomarkers, Tumor; Humans; Neoplasms; Oligopeptides; Protein Precursors; Thymalfasin; Thymopentin; Thymosin; Thymus Hormones

2000
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.
    International journal of immunopharmacology, 2000, Volume: 22, Issue:12

    Many studies have explored the effects of immunotherapy, alone or in combination with conventional therapies, on both experimental and human cancers. Evidence has been provided that combined treatments with thymosin alpha 1 (T alpha 1) and low doses of interferon (IFN) or interleukin (IL)-2 are highly effective in restoring several immune responses depressed by tumor growth and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to increase the anti-tumor effect of chemotherapy while markedly reducing the general toxicity of the treatment. The advantages of using this combined chemo-immunotherapeutic approach in experimental and human cancers are reviewed in this issue.

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Combined Modality Therapy; Humans; Immunotherapy; Neoplasms; Thymalfasin; Thymosin

2000
Thymosin alpha-1 as adjunct for conventional therapy of malignant tumors: a review.
    Cancer investigation, 1994, Volume: 12, Issue:5

    T alpha 1, a 28-amino-acid peptide, is derived from PT alpha, which is an intracellular, nonsecretory protein of unknown function. Both T alpha 1 and PT alpha are found in the blood of normal individuals. Subcutaneous and intramuscular injections of T alpha 1 in doses up to 9.6 mg/m2 are tolerated without side effects, and 0.9 mg/m2 injections raise the serum level approximately 30-fold after 1 hr of administration, which slowly returns to baseline within 24 hr. In vitro, and perhaps in vivo, T alpha 1 restores normal T-cell function. It increases IL-2 production and IL-2 receptors in normal mitogen-stimulated T cells and stimulates IL-3 production in immunocompromised mice. The dose-response relationship for these effects is not linear and may be bimodal. T alpha 1 binds to VIP receptors and inhibits in vitro and xenograft growth of non-SCLC cell lines. In patients with nonbulky carcinomas who have received standard therapy, T alpha 1 is possibly effective in prolonging the time to relapse and in improving survival. At present there is a great need to clearly define the clinical role of T alpha 1 in cancer patients. A major problem encountered in studies with T alpha 1 will, however, be the present lack of knowledge with regard to its mechanism in effecting tumor growth. It is not at all clear whether its immunomodulatory functions, its interaction with VIP receptors, or none of these mechanisms are related to its antineoplastic activities. In addition, the apparent nonlinear dose-response relationship will make it difficult to choose a reasonable dosing schedule for clinical trials. This is particularly apparent in light of the experimental animal data summarized above where a tumor response was seen at doses of 4 micrograms/kg and 400 micrograms/kg but not at 0.4 microgram/kg and 40 micrograms/kg. This dose range could conceivably be given to humans since 9.6 mg/m2, the maximum dose given to humans without major side effects to date, is roughly equivalent to 250 micrograms/kg. At this time a reasonable clinical approach would be a well-designed risk factor stratified phase III clinical trial using 0.9 mg/m2 T alpha 1 subcutaneously twice a week compared to a control group to substantiate the data reported by Schulof et al. Before such data are available, T alpha 1 should not be used in clinical oncology.

    Topics: Adjuvants, Immunologic; Animals; Clinical Trials as Topic; Humans; Mice; Neoplasms; Thymalfasin; Thymosin

1994
Clinical applications of thymosin alpha-1.
    Cancer investigation, 1994, Volume: 12, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Humans; Neoplasms; Thymalfasin; Thymosin

1994

Trials

1 trial(s) available for thymalfasin and Neoplasms

ArticleYear
The thymosins--preclinical and clinical studies with fraction V and alpha-I.
    Cancer treatment reviews, 1984, Volume: 11, Issue:1

    Topics: Antigens, Surface; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Humans; Kinetics; Leukocyte Count; Lung Neoplasms; Lymphocyte Culture Test, Mixed; Neoplasms; Rosette Formation; T-Lymphocytes; Thymalfasin; Thymosin

1984

Other Studies

11 other study(ies) available for thymalfasin and Neoplasms

ArticleYear
Thymosin α-1 in cancer therapy: Immunoregulation and potential applications.
    International immunopharmacology, 2023, Volume: 117

    Thymosin α-1 (Tα-1) is an immunomodulating polypeptide of 28 amino acids, which was the first peptide isolated from thymic tissue and has been widely used for the treatment of viral infections, immunodeficiencies, and especially malignancies. Tα-1 stimulates both innate and adaptive immune responses, and its regulation of innate immune cells and adaptive immune cells varies under different disease conditions. Pleiotropic regulation of immune cells by Tα-1 depends on activation of Toll-like receptors and its downstream signaling pathways in various immune microenvironments. For treatment of malignancies, the combination of Tα-1 and chemotherapy has a strong synergistic effect by enhancing the anti-tumor immune response. On the basis of the pleiotropic effect of Tα-1 on immune cells and the promising results of preclinical studies, Tα-1 may be a favorable immunomodulator to enhance the curative effect and decrease immune-related adverse events of immune checkpoint inhibitors to develop novel cancer therapies.

    Topics: Adjuvants, Immunologic; Humans; Immunity; Neoplasms; Thymalfasin; Thymosin; Tumor Microenvironment

2023
Thymosin α1 interacts with Galectin-1 modulating the β-galactosides affinity and inducing alteration in the biological activity.
    International immunopharmacology, 2023, Volume: 118

    The study of mechanism of action of Thymosin alpha 1 (Tα1) and the basis of the pleiotropic effect in health and disease, is one of the main focus of our ongoing research. Tα1 is a thymic peptide that demonstrates a peculiar ability to restore homeostasis in different physiological and pathological conditions (i.e., infections, cancer, immunodeficiency, vaccination, and aging) acting as multitasking protein depending on the host state of inflammation or immune dysfunction. However, few are the information about mechanisms of action mediated by specific Tα1-target protein interaction that could explain its pleiotropic effect. We investigated the interaction of Tα1 with Galectin-1 (Gal-1), a protein belonging to an oligosaccharide binding protein family involved in a variety of biological and pathological processes, including immunoregulation, infections, cancer progression and aggressiveness. Using molecular and cellular methodological approaches, we demonstrated the interaction between these two proteins. Tα1 specifically inhibited the hemagglutination activity of Gal-1, the Gal-1 dependent in vitro formation of endothelial cell tubular structures, and the migration of cancer cells in wound healing assay. Physico-chemical methods revealed the details of the molecular interaction of Tα1 with Gal-1. Hence, the study allowed the identification of the not known until now specific interaction between Tα1 and Gal-1, and unraveled a novel mechanism of action of Tα1 that could support understanding of its pleiotropic activity.

    Topics: Galectin 1; Humans; Neoplasms; Thymalfasin; Thymosin

2023
PASylated Thymosin α1: A Long-Acting Immunostimulatory Peptide for Applications in Oncology and Virology.
    International journal of molecular sciences, 2020, Dec-24, Volume: 22, Issue:1

    Topics: Acetylation; Acetyltransferases; Adjuvants, Immunologic; Animals; COVID-19 Drug Treatment; Escherichia coli; Escherichia coli Proteins; Female; Half-Life; Mass Spectrometry; Microscopy, Electron, Scanning; Neoplasms; Peptides; Proteolysis; Rats; Rats, Wistar; Recombinant Fusion Proteins; Ribosomal Proteins; Thymalfasin; Virus Diseases

2020
Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs half-life and enhances antitumor effects in vivo.
    International immunopharmacology, 2019, Volume: 74

    Thymosin alpha 1 (Tα1) is an immunomodulatory polypeptide secreted from the thymus. Tα1 has a wide range of biological functions, such as immunomodulation and endocrine regulation. Tα1 also displays antiviral and antitumor activities. Tα1 has been successfully used in clinical adjuvant therapy for solid tumors to improve the immune response of patients undergoing chemotherapy and radiotherapy. However, the half-life of Tα1 in the body is short, so frequent administration is required to maintain efficacy. In order to improve the pharmacokinetic profile of Tα1, we linked the mutated CH3 (mCH3) fragment of IgG1 (human) to the C-terminus of Tα1 to produce a long-acting fusion protein, Tα1-mCH3. The half-life of Tα1-mCH3 (47 h) was substantially increased compared with that of the parent molecule Tα1 (3 h). In vivo studies indicated that mCH3 fusion retained the original biological activity of Tα1, and Tα1-mCH3 showed slightly better immunomodulatory effect than Ta1. In the 4 T1 and B16F10 tumor xenograft models, Tα1-mCH3 induced a greater abundance of CD4

    Topics: Animals; Antineoplastic Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytokines; Female; Half-Life; Immunoglobulin Fragments; Immunoglobulin G; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Mutation; Neoplasms; Rats, Sprague-Dawley; Recombinant Fusion Proteins; Thymalfasin

2019
Deciphering cellular biological processes to clinical application: a new perspective for Tα1 treatment targeting multiple diseases.
    Expert opinion on biological therapy, 2018, Volume: 18, Issue:sup1

    Thymosin alpha 1 (Tα1) is a well-recognized immune response modulator in a wide range of disorders, particularly infections and cancer. The bioinformatic analysis of public databases allows drug repositioning, predicting a new potential area of clinical intervention. We aimed to decipher the cellular network induced by Tα1 treatment to confirm present use and identify new potential clinical applications.. We used the transcriptional profile of human peripheral blood mononuclear cells treated in vitro with Tα1 to perform the enrichment network analysis by the Metascape online tools and the disease enrichment analysis by the DAVID online tool.. Networked cellular responses reflected Tα1 regulated biological processes including immune and metabolic responses, response to compounds and oxidative stress, ion homeostasis, peroxisome biogenesis and drug metabolic process. Beyond cancer and infections, the analysis evidenced the association with disorders such as kidney chronic failure, diabetes, cardiovascular, chronic respiratory, neuropsychiatric, neurodegenerative and autoimmune diseases.. In addition to the known ability to promote immune response pathways, the network enrichment analysis demonstrated that Tα1 regulates cellular metabolic processes and oxidative stress response. Notable, the analysis highlighted the association with several diseases, suggesting new translational implication of Tα1 treatment in pathological conditions unexpected until now.

    Topics: Autoimmune Diseases; Biological Phenomena; Gene Expression Profiling; Gene Regulatory Networks; Humans; Infections; Leukocytes, Mononuclear; Microarray Analysis; Neoplasms; Signal Transduction; Thymalfasin; Transcriptome

2018
Biomedicine. Thymosins: clinical promise after a decades-long search.
    Science (New York, N.Y.), 2007, May-04, Volume: 316, Issue:5825

    Topics: Animals; Cell Movement; Clinical Trials as Topic; Corneal Injuries; Eye Injuries; Humans; Myocardial Infarction; Neoplasms; Neovascularization, Physiologic; Thymalfasin; Thymosin; Wound Healing

2007
[Effect of thymosin alpha 1 on cellular immune function in elderly patients with malignant tumor].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2003, Volume: 32, Issue:4

    To investigate the effect of thymosin alpha 1 on cellular immune function in the elderly patients with malignant tumor.. Thirty patients with malignant tumor were injected with thymosin alpha 1 subcutaneously at the dose of 1.6 mg q.d. for the first month and q.o.d. for the following month. The number of T cell subgroups and the activity of NK cell in peripheral blood were detected and the quality of life of the patients were evaluated before treatment and at the end of treatment.. Treatment of thymosin alpha 1 increased the number of CD4 cells and improved the NK activity, and also improved the quality of life of the elderly patients with malignant tumor. There were no side effects found.. Thymosin alpha 1 can enhance the cellular immune function of the elderly patients with malignant tumor.

    Topics: Aged; Aged, 80 and over; CD4 Lymphocyte Count; Female; Humans; Killer Cells, Natural; Male; Neoplasms; Quality of Life; Thymalfasin; Thymosin

2003
Development of ELISA to estimate thymosin alpha1, the N terminus of prothymosin alpha, in human tumors.
    Clinical chemistry, 1997, Volume: 43, Issue:1

    We reported that tumor content of prothymosin alpha (ProT alpha) is a proliferation index of human breast tumors that might be used to identify patients at high risk for distant metastasis (Dominguez et al., Eur J Cancer 1993; 29A:893-7). In that study ProT alpha concentrations were measured by a RIA; here we present an alternative nonisotopic assay that could be used in a standard clinical laboratory. Main features of the ELISA are: (a) A recombinant fusion protein glutathione S-transferase (GST)-human ProT alpha was used to coat the microtiter plates; (b) we used a polyclonal antiserum raised in rabbits that detects thymosin alpha1, the NH2-terminal fragment of ProT alpha; (c) it is as sensitive as the RIA; (d) it is faster than the RIA. ProT alpha concentrations in various human tumors (skin, esophagus, colorectal, and breast) as assessed by ELISA were comparable with, although twofold greater than, the values previously estimated by RIA.

    Topics: Antibody Specificity; Enzyme-Linked Immunosorbent Assay; Humans; Immune Sera; Neoplasms; Peptide Fragments; Protein Precursors; Regression Analysis; Sensitivity and Specificity; Thymalfasin; Thymosin

1997
An immunological approach to aging.
    Annals of the New York Academy of Sciences, 1992, Dec-26, Volume: 673

    Topics: Aging; Animals; Immune System; Incidence; Longevity; Male; Mice; Mice, Inbred Strains; Neoplasms; Peptide Fragments; Thymalfasin; Thymosin

1992
Phase II trial of thymosin fraction 5 and thymosin alpha 1.
    Journal of biological response modifiers, 1987, Volume: 6, Issue:3

    Previous Phase I trials have established the safety of administering thymosin fraction 5 and thymosin alpha 1 to patients with advanced cancer. These same trials also suggested potential immune-enhancing doses of these agents. In this study, 12 patients with colon cancer were treated with thrice weekly thymosin fraction 5 at a dose of 120 mg/m2, and 10 patients with non-small-cell lung cancer received thymosin alpha 1 at 1.2 mg/m2 thrice weekly. Five patients with hypernephroma also received one or both agents by a thrice weekly schedule. There were no tumor responses observed in any of these patients, and immune enhancement was neither obtained nor sustained. We conclude that at these doses and schedules, these hormones have very limited, if any, antitumor properties and that they are incapable of producing immune augmentation as defined by the assays used in this study.

    Topics: Drug Evaluation; Female; Humans; In Vitro Techniques; Lymphocyte Activation; Male; Middle Aged; Neoplasms; Thymalfasin; Thymosin

1987
In vivo immune restoration in advanced cancer patients after administration of thymosin fraction 5 or thymosin alpha 1.
    Journal of biological response modifiers, 1983, Volume: 2, Issue:2

    Since patients with advanced cancer are usually immunodeficient, they might benefit from therapy with thymic hormones, which have an immunorestorative effect in immunosuppressed laboratory animals. We treated 14 patients with thymosin fraction 5 (TF5), and 14 patients with thymosin alpha 1 (TA1) over the dose ranges of 60-960 mg/m2 and 0.6-9.6 mg/m2, respectively. In addition to monitoring toxicity, we studied patients extensively using a variety of lymphocyte cell surface markers and in vitro functional assays, both before and following treatment. Approximately one-half of the in vitro tests were abnormal in the cancer patients prior to treatment. Overall, 28.4 and 18.3% of abnormal tests were improved following TA1 and TF5, respectively. On the other hand, 16% of normal tests became abnormal after therapy. Most of these responses occurred within 24-48 h and seldom persisted beyond 72 h. An optimum dose of TF5 was not readily identified, but 1.2 mg/m2 of TA1 was associated with substantial improvement in 46% of abnormal tests. Twelve of 14 cancer patients who received TF5 and 13 of 14 who received TA1 showed significant improvement in at least one in vitro test. Tumor responses were not seen, but the study suggested thymosin treatments would need to be repeated every 2-3 days to sustain an immune response. TF5 and TA1 are well tolerated as single i.m. injections, and have immunorestorative potential in cancer patients. Additional studies with repeated thymosin doses in more homogeneous cancer populations appear to be justified.

    Topics: Female; Herpesvirus 3, Human; Humans; Immunity; Lymphocytes; Male; Middle Aged; Neoplasms; Thymalfasin; Thymosin; Time Factors

1983